What's Happening?
Nirrin Technologies has launched TALOS, a new protein quantitation system designed to streamline biopharmaceutical manufacturing workflows. The system utilizes High-Precision Tunable Laser Spectroscopy
(HPTLS) technology to replace traditional UV-based methods, offering a more reliable and consistent approach to protein quantitation. TALOS is capable of measuring protein concentrations from 0.1 to 250 mg/mL in seconds from a small sample, without the need for dilution or complex calibration. This innovation aims to simplify operations and reduce workflow burdens across various stages of biopharmaceutical development and manufacturing, from process development to GMP manufacturing. The system is designed for flexible deployment, supporting at-line, in-line, and in situ measurements, which enhances its applicability across different unit operations and manufacturing sites.
Why It's Important?
The introduction of TALOS by Nirrin Technologies is significant for the biopharmaceutical industry as it addresses the complexities and limitations of traditional protein quantitation methods. By providing a more consistent and transferable approach, TALOS can enhance the efficiency and reliability of biopharmaceutical manufacturing processes. This is particularly important as the industry moves towards more distributed and automated manufacturing models. The ability to perform rapid and accurate protein quantitation can lead to improved process understanding and faster development timelines, ultimately benefiting companies by reducing costs and accelerating the time-to-market for new therapies. Additionally, the system's compliance with GMP standards ensures that it meets the regulatory requirements necessary for biopharmaceutical production.
What's Next?
Nirrin Technologies plans to expand the availability of TALOS across North America, Europe, and Japan. The company is also developing additional configurations, such as in-line flow cells and in situ probes, to enable continuous real-time protein monitoring during processing. These advancements could further enhance the system's utility and integration into existing manufacturing workflows. As the system becomes more widely adopted, it may prompt other companies to innovate and improve their own bioprocessing technologies, potentially leading to broader advancements in the biopharmaceutical industry.
